Received Aug 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | G334J | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Z39XM | — |
48 year old patient that got 2 doses of Bexsaro; 48 year old patient that got 2 doses of Bexsaro; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 48-year-old male patient who received Men B NVS (Bexsero) (batch number G334J, expiry date 31-OCT-2027) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) (batch number Z39XM, expiry date 31-OCT-2026) for prophylaxis. On 06-JUN-2025, the patient received the 2nd dose of Bexsero. On 01-MAY-2025, the patient received the 1st dose of Bexsero. On 01-MAY-2025, not applicable after receiving Bexsero and an unknown time after receiving Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: 48 year old patient that got 2 doses of Bexsaro). On 06-JUN-2025, the patient experienced inappropriate age at vaccine administration (Verbatim: 48 year old patient that got 2 doses of Bexsaro). The outcome of the inappropriate age at vaccine administration and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-JUL-2025 Reporter stated that a 48 year old patient that got 2 doses of Bexsaro which is not approved for over 25 years of age, which led to Inappropriate age at vaccine administration. Also stated that he is not immunocompromised and he was going to nursing school so they assume that is why.